Subramaniam S, Ruf W, Bosmann M
Br J Pharmacol. 2021; 179(10):2086-2099.
PMID: 34235728
PMC: 8794588.
DOI: 10.1111/bph.15587.
Mwirigi J, Kume M, Hassler S, Ahmad A, Ray P, Jiang C
J Pain. 2021; 22(6):692-706.
PMID: 33429107
PMC: 8197731.
DOI: 10.1016/j.jpain.2020.12.006.
Tharappel A, Samrat S, Li Z, Li H
ACS Infect Dis. 2020; 6(11):2844-2865.
PMID: 33112126
PMC: 7605336.
DOI: 10.1021/acsinfecdis.0c00456.
Wang M, An S, Wang D, Ji H, Guo X, Wang Z
J Immunol Res. 2018; 2018:4735752.
PMID: 30363984
PMC: 6186345.
DOI: 10.1155/2018/4735752.
Kihara H, Kim D, Nagai M, Nojiri T, Nagai S, Chen C
Int J Oral Sci. 2018; 10(3):21.
PMID: 29961761
PMC: 6026594.
DOI: 10.1038/s41368-018-0022-1.
Skin neurogenic inflammation.
Choi J, Di Nardo A
Semin Immunopathol. 2018; 40(3):249-259.
PMID: 29713744
PMC: 6047518.
DOI: 10.1007/s00281-018-0675-z.
The Role of Proteinase-Activated Receptors 1 and 2 in the Regulation of Periodontal Tissue Metabolism and Disease.
Rovai E, Holzhausen M
J Immunol Res. 2017; 2017():5193572.
PMID: 28503577
PMC: 5414592.
DOI: 10.1155/2017/5193572.
TRPV1 and TRPA1 in cutaneous neurogenic and chronic inflammation: pro-inflammatory response induced by their activation and their sensitization.
Gouin O, LHerondelle K, Lebonvallet N, Le Gall-Ianotto C, Sakka M, Buhe V
Protein Cell. 2017; 8(9):644-661.
PMID: 28364279
PMC: 5563280.
DOI: 10.1007/s13238-017-0395-5.
PAR2 Modulators Derived from GB88.
Yau M, Liu L, Suen J, Lim J, Lohman R, Jiang Y
ACS Med Chem Lett. 2016; 7(12):1179-1184.
PMID: 27994760
PMC: 5150695.
DOI: 10.1021/acsmedchemlett.6b00306.
Protease activated receptors in cardiovascular function and disease.
Barnes J, Singh S, Gomes A
Mol Cell Biochem. 2016; 263(1):227-39.
PMID: 27520681
DOI: 10.1023/B:MCBI.0000041864.14092.5b.
Protective role of Kalpaamruthaa in type II diabetes mellitus-induced cardiovascular disease through the modulation of protease-activated receptor-1.
Latha R, Shanthi P, Sachdanandam P
Pharmacogn Mag. 2015; 11(Suppl 1):S209-16.
PMID: 26109768
PMC: 4461962.
DOI: 10.4103/0973-1296.157739.
Protease-activated receptor 4: a critical participator in inflammatory response.
Fu Q, Cheng J, Gao Y, Zhang Y, Chen X, Xie J
Inflammation. 2014; 38(2):886-95.
PMID: 25120239
DOI: 10.1007/s10753-014-9999-6.
Periodontal treatment downregulates protease-activated receptor 2 in human gingival crevicular fluid cells.
Tubero Euzebio Alves V, da Silva H, Franca B, Eichler R, Saraiva L, de Carvalho M
Infect Immun. 2013; 81(12):4399-407.
PMID: 24042113
PMC: 3837994.
DOI: 10.1128/IAI.01107-13.
Effects of protease-activated receptors (PARs) on intracellular calcium dynamics of acinar cells in rat lacrimal glands.
Oikawa M, Saino T, Kimura K, Kamada Y, Tamagawa Y, Kurosaka D
Histochem Cell Biol. 2013; 140(4):463-76.
PMID: 23463389
DOI: 10.1007/s00418-013-1082-0.
Effect of PAR2 in regulating TNF-α and NAD(P)H oxidase in coronary arterioles in type 2 diabetic mice.
Park Y, Yang J, Zhang H, Chen X, Zhang C
Basic Res Cardiol. 2010; 106(1):111-23.
PMID: 20972877
PMC: 3143573.
DOI: 10.1007/s00395-010-0129-9.
Nafamostat mesilate, a potent tryptase inhibitor, modulates periodontitis in rats.
Holzhausen M, Balejo R, Lara G, Cortelli S, Saad W, Cortelli J
Clin Oral Investig. 2010; 15(6):967-73.
PMID: 20820824
DOI: 10.1007/s00784-010-0463-1.
Immunodominant antigens in Naegleria fowleri excretory--secretory proteins were potential pathogenic factors.
Kim J, Yang A, Sohn H, Kim D, Song K, Shin H
Parasitol Res. 2009; 105(6):1675-81.
PMID: 19756751
DOI: 10.1007/s00436-009-1610-y.
Novel antagonists for proteinase-activated receptor 2: inhibition of cellular and vascular responses in vitro and in vivo.
Kanke T, Kabeya M, Kubo S, Kondo S, Yasuoka K, Tagashira J
Br J Pharmacol. 2009; 158(1):361-71.
PMID: 19719785
PMC: 2795266.
DOI: 10.1111/j.1476-5381.2009.00342.x.
Thrombin increases inflammatory cytokine and angiogenic growth factor secretion in human adipose cells in vitro.
Strande J, Phillips S
J Inflamm (Lond). 2009; 6:4.
PMID: 19267924
PMC: 2661073.
DOI: 10.1186/1476-9255-6-4.
Association of TMPRSS2 and KLK11 gene expression levels with clinical progression of human prostate cancer.
Bi X, He H, Ye Y, Dai Q, Han Z, Liang Y
Med Oncol. 2009; 27(1):145-51.
PMID: 19242826
DOI: 10.1007/s12032-009-9185-0.